[Subjective well-being and ability to work after SARS-CoV-2 immunization with the vector vaccine ChAdOx1-S (AstraZeneca COVID-19 vaccine)].

Johannes KalbhennFeline GablerSebastian HeinrichDaniel Steinmann

Published in: Zentralblatt fur Arbeitsmedizin, Arbeitsschutz und Ergonomie (2021)

Vaccination with ChAdOx1‑S frequently resulted in side effects. These resulted in 37% of respondents reporting sick. Nevertheless, 89.6% of all respondents would choose coronavirus vaccination with ChAdOx1‑S again.

Keyphrases

sars cov
respiratory syndrome coronavirus
coronavirus disease
adverse drug
sleep quality
depressive symptoms